Comprehensive Stock Analysis of First Majestic Silver Corp.(NYSE:AG): Arena Pharmaceuticals, Inc.(NASDAQ:ARNA)

0
10

First Majestic Silver Corp. (AG) will report its next earnings on Aug 07 BMO. The company reported the earnings of $0/Share in the last quarter where the estimated EPS by analysts was $0.01/share. The difference between the expected and actual EPS was $-0.01/share, which represents an Earnings surprise of -100%.

Many analysts are providing their Estimated Earnings analysis for First Majestic Silver Corp. and for the current quarter 2 analysts have projected that the stock could give an Average Earnings estimate of $-0.02/share. These analysts have also projected a Low Estimate of $-0.02/share and a High Estimate of $-0.01/share.

In case of Revenue Estimates, 1 analysts have provided their consensus Average Revenue Estimates for First Majestic Silver Corp. as 66 Million. According to these analysts, the Low Revenue Estimate for First Majestic Silver Corp. is 66 Million and the High Revenue Estimate is 66 Million. The company had Year Ago Sales of 66.17 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for AG to be 233.3%. They are projecting Next Quarter growth of 200%. For the next 5 years, First Majestic Silver Corp. is expecting Growth of 321.43% per annum, whereas in the past 5 years the growth was 133.33% per annum.

Some buy side analysts are also providing their Analysis on First Majestic Silver Corp., where 4 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 3 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

First Majestic Silver Corp. closed its last trading session at $9.63 with the gain of 3.53%. The Market Capitalization of the company stands at 2.03 Billion. The Company has 52-week high of $11.62 and 52-week low of $4.59. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -3.76% where SMA50 and SMA200 are -0.11% and 39.12% respectively. The Company Touched its 52-Week High on 09/03/19 and 52-Week Low on 11/30/18.

The Relative Volume of the company is 0.56 and Average Volume (3 months) is 5.54 million. The company’s P/E (price to earnings) ratio is 0 and Forward P/E ratio of 142.43.

The company shows its Return on Assets (ROA) value of 0%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is 0%.

While looking at the Stock’s Performance, First Majestic Silver Corp. currently shows a Weekly Performance of 1.94%, where Monthly Performance is -5.05%, Quarterly performance is 35.09%, 6 Months performance is 43.66% and yearly performance percentage is 74.61%. Year to Date performance value (YTD perf) value is 69.27%. The Stock currently has a Weekly Volatility of 5.22% and Monthly Volatility of 5.00%.

Arena Pharmaceuticals, Inc. (ARNA) will report its next earnings on Aug 07 AMC. The company reported the earnings of $-1.24/Share in the last quarter where the estimated EPS by analysts was $-1.08/share. The difference between the expected and actual EPS was $-0.16/share, which represents an Earnings surprise of -14.8%.

Many analysts are providing their Estimated Earnings analysis for Arena Pharmaceuticals, Inc. and for the current quarter 10 analysts have projected that the stock could give an Average Earnings estimate of $-1.32/share. These analysts have also projected a Low Estimate of $-1.48/share and a High Estimate of $-1.17/share.

In case of Revenue Estimates, 9 analysts have provided their consensus Average Revenue Estimates for Arena Pharmaceuticals, Inc. as 2.06 Million. According to these analysts, the Low Revenue Estimate for Arena Pharmaceuticals, Inc. is 890 Million and the High Revenue Estimate is 3.75 Million. The company had Year Ago Sales of 3.57 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for ARNA to be -94.3%. They are projecting Next Quarter growth of -71.95%. For the next 5 years, Arena Pharmaceuticals, Inc. is expecting Growth of -168.27% per annum, whereas in the past 5 years the growth was 388.47% per annum.

Some buy side analysts are also providing their Analysis on Arena Pharmaceuticals, Inc., where 3 analysts have rated the stock as Strong buy, 0 analysts have given a Buy signal, 0 said it’s a HOLD, and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Arena Pharmaceuticals, Inc. might touch $79 high while the Average Price Target and Low price Target is $69 and $59 respectively.

Arena Pharmaceuticals, Inc. closed its last trading session at $52.28 with the loss of -2.08%. The Market Capitalization of the company stands at 2.62 Billion. The Company has 52-week high of $64.48 and 52-week low of $31.97. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -3.07% where SMA50 and SMA200 are -10.07% and 1.81% respectively. The Company Touched its 52-Week High on 08/01/19 and 52-Week Low on 11/14/18.

The Relative Volume of the company is 1.01 and Average Volume (3 months) is 462.91 million. The company’s P/E (price to earnings) ratio is 4.43 and Forward P/E ratio of 0.

The company shows its Return on Assets (ROA) value of 60.7%. The Return on Equity (ROE) value stands at 66.2%. While it’s Return on Investment (ROI) value is -5.2%.

While looking at the Stock’s Performance, Arena Pharmaceuticals, Inc. currently shows a Weekly Performance of -2.64%, where Monthly Performance is -10.11%, Quarterly performance is -8.8%, 6 Months performance is 12.11% and yearly performance percentage is 21.76%. Year to Date performance value (YTD perf) value is 31.42%. The Stock currently has a Weekly Volatility of 3.30% and Monthly Volatility of 3.47%.

SHARE